357 filings
Page 4 of 18
8-K
z18 xwf0mw49el9t3s
23 Jan 20
Entry into a Material Definitive Agreement
4:07pm
8-K
8uu7szcwz743e
22 Jan 20
ImmunoGen Announces Proposed Public Offering of Common Stock
4:09pm
8-K
v5azvz
13 Jan 20
Results of Operations and Financial Condition
6:07am
8-K
k4o0pz52o4ty1h
20 Dec 19
Departure of Directors or Certain Officers
7:03am
8-K
g4ja1hva75puqrkdq6
17 Dec 19
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
jatg4xuxhb 20ey65o9g
26 Nov 19
Entry into a Material Definitive Agreement
4:45pm
8-K
c1aals8s8lrxk
1 Nov 19
ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
6:54am
8-K
d2yiaehk
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K/A
lvevm2
5 Aug 19
Cost Associated with Exit or Disposal Activities
8:55am
8-K/A
3vzp8dm1p0w 9nyp7wq
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
10:33am
8-K
746favl5wao hzpt0
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
6:38am
8-K
c4f37tuoamxuf1k h10
27 Jun 19
ImmunoGen Announces Completion of Operational Review
6:35am
8-K
x4uop86f2l 6o1
24 Jun 19
Submission of Matters to a Vote of Security Holders
11:54am
8-K
yoc 864ah9tnxrknv
15 May 19
Other Events
6:39am
8-K
65cd6o2yp3 yli22p
3 May 19
ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
6:36am
8-K
j69vcm1e 90
1 Mar 19
Entry into a Material Definitive Agreement
7:02am
8-K
nohh3pmju5sdku36
8 Feb 19
ImmunoGen Reports Recent Progress and 2018 Operating Results
6:37am
8-K/A
p3j1zotj8
8 Jan 19
Results of Operations and Financial Condition
4:59pm
8-K
w3wp3 i2yz370rg
8 Jan 19
Results of Operations and Financial Condition
4:07pm
8-K
ee04ns dvnpvg3g391j
8 Jan 19
Entry into a Material Definitive Agreement
4:05pm